

October 4, 2022

**PROVIDER ALERT: COVERAGE AND REIMBURSEMENT RATE FOR  
BEBTELOVIMAB 175**

The billing and reimbursement rates for the administration of COVID-19 Monoclonal Antibody infusions are based on the published guidance by CMS. Bebtelovimab 175 is no longer being provided by the U.S. government free of charge.

The chart below provides the coverage effective date and reimbursement rate.

HCPCS	DESCRIPTION	LABELER	COVERAGE/RATE
Q0222	Bebtelovimab 175	Eli Lilly	2/11/22 - 8/14/22 Not Covered Effective 8/15/22 Covered \$2,394.00

For questions concerning this Provider Alert, please contact the MFC-DC Provider Relations department, Monday through Friday, 8 a.m. to 5:30 p.m.

Phone: **855-798-4244, Option 2**

Email: [mfcdc-providerrelations@medstar.net](mailto:mfcdc-providerrelations@medstar.net)